We are live on ! Find out more
AEON.WS

AEON Biopharma Inc
AEON.WS

Delisted

AEON.WS was delisted on the 26th of April, 2024.

Back to rankings

52 hedge funds and large institutions have $6.9M invested in AEON Biopharma Inc in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

4% more funds holding

Funds holding: 50 → 52 (+2)

1% less capital invested

Capital invested by funds: $6.98M → $6.9M (-$85.8K)

Holders
52
Holders Change
+2
Holders Change %
+4%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
5
Closed
4
Calls
$1M
Puts
–
Net Calls
+$1M
Net Calls Change
-$38K

Top Buyers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
+$98.1K
2
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$57.5K
3
SCM
Shaolin Capital Management
Florida
+$33.3K
4
UOC
UBS O'Connor
Illinois
+$26K
5
RA
Ramius Advisors
New York
+$20.1K

Top Sellers

Rank Fund Capital Flow
1
CC
Covalis Capital
United Kingdom
-$180K
2
ECP
Empyrean Capital Partners
California
-$147K
3
Citadel Advisors
Citadel Advisors
Florida
-$36.4K
4
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$36K
5
FTCM
Fir Tree Capital Management
New York
-$841
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$10K – – –
GPCM
27
Granite Point Capital Management
Massachusetts
$10K – – –
AR
28
Advisory Research
Illinois
$8K – – –
AA
29
AQR Arbitrage
Connecticut
$8K – – –
DCM
30
Dupont Capital Management
Delaware
$8K – – –
AGM
31
Alpine Global Management
New York
$8K +$10.5K +50,100 New
FCM
32
Farallon Capital Management
California
$7K – – –
FIG
33
Fortress Investment Group
New York
$7K – – –
Nomura Holdings
34
Nomura Holdings
Japan
$6K – – –
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$5K – – –
ESCM
36
Echo Street Capital Management
New York
$5K – – –
MCM
37
Moore Capital Management
New York
$5K – – –
ACA
38
Arena Capital Advisors
California
$4K – – –
CC
39
Centiva Capital
New York
$4K – – –
EH
40
EMG Holdings
Connecticut
$4K – – –
PAMP
41
Polar Asset Management Partners
Ontario, Canada
$4K – – –
SSA
42
Schonfeld Strategic Advisors
New York
$3K +$4.81K +22,865 New
OMC
43
Old Mission Capital
Illinois
$2K -$149 -707 -4%
RCM
44
Rivernorth Capital Management
Florida
$2K – – –
TCM
45
Tegean Capital Management
New York
$2K – – –
CS
46
Clear Street
New York
$2K +$3.37K +16,045 +7,068%
AA
47
Ancora Advisors
Ohio
$1K – – –
SCM
48
Segantii Capital Management
Hong Kong
$163 – – –
MF
49
Magnetar Financial
Illinois
$9 +$12.6K +59,732 New
ECP
50
Empyrean Capital Partners
California
– -$147K -466,666 Closed
1
2
3

AEON.WS Hedge Fund Activity: Q2 2022 in Review

52 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q2 2022, worth a combined $6.9M — down 1.2% from $6.98M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AEON.WS positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Cantor Fitzgerald, adding an estimated $98.1K. The largest seller was Covalis Capital, exiting entirely with an estimated $180K sold.

  • 52 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q2 2022, up from 50 in Q1 2022.
  • Funds reported $6.9M of AEON Biopharma Inc stock for Q2 2022, down 1.2% quarter-over-quarter.
  • 6 funds opened new AEON Biopharma Inc positions in Q2 2022 and 4 closed out, a net change of +2 holders.
  • The largest AEON Biopharma Inc buyer in Q2 2022 was Cantor Fitzgerald, an estimated $98.1K added.
  • The largest AEON Biopharma Inc seller in Q2 2022 was Covalis Capital, an estimated $180K sold.

Based on aggregated 13F filings for Q2 2022.